Britain’s drug regulator authorized the Alzheimer’s drug Kisunla on Wednesday, but The federal government received’t be purchasing it right after an independent watchdog agency explained the treatment isn’t definitely worth the Price to taxpayersWhat wellbeing industry experts think of the rising copyright “microdosing” development that